Highlights
PharmaMarketing USA Summit
We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the e
Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel
Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 200450
Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection,
Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntari
Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection,
Audience: Health Professional, Pharmacy nlnlnlnlnlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer co
First Rheumatoid Arthritis Patient Dosed in Phase â…¢ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as '
Merck Provides U.S. Regulatory Update on Gefapixant
RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Can
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful
nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint,
Marburg vaccine tested at Texas Biomed moves to Phase 2 clinical trials
SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is prog
ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Tria
SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies b
FDA Approves Filsuvez (birch triterpenes) Topical Gel for the Treatment of Epidermolysis B
BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established t
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across
nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoa
FDA Approves Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with P
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Fo